{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-061851","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.417367+00:00","generated_at":"2026-05-23T00:15:41.306382+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptive Biotechnologies Q1 revenue up 25% to $52.4M; raises MRD guidance","bullets":["Q1 revenue $52.4M (+25% YoY); MRD revenue $43.7M (+34%); clonoSEQ volume up 36% to 23,117 tests.","Net loss narrowed to $29.8M from $47.5M; adjusted EBITDA loss $12.7M from $28.2M.","Raises FY 2025 MRD revenue guidance to $180-190M (from $175-185M); lowers cash burn target to $50-60M.","Expanded Medicare coverage for clonoSEQ in mantle cell lymphoma recurrence monitoring.","Cash, equivalents, and marketable securities $232.8M at March 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-061851","json":"https://secwatch.observer/filing/0000950170-25-061851.json","markdown":"https://secwatch.observer/filing/0000950170-25-061851.md","text":"https://secwatch.observer/filing/0000950170-25-061851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017025061851/0000950170-25-061851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017025061851/adpt-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:15:41.306382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}